fda glp-1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA and Novo Nordisk Warned

These are the same medications that people are talking about and getting real results with all over social media

Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) , in StatPearls

The biological activities of GLP-1 include stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake

The large molecular entities of both albiglutide and dulaglutide delay their renal clearance (92, 93)

The FDA has received reports of serious gastrointestinal issues related to Ozempic, yet the label only lists a possibility of severe gastric reactions, without listing specific types of reactions, other than ileus

Sign up for the Bodywork newsletter.